Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1618

  • Showing results for hiv reservoir. Search instead for hivreservoir (1 item)
1.

Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Polizzotto MN, Chen G, Tressler RL, Godfrey C.

Drugs. 2015 Jul 30. [Epub ahead of print]

PMID:
26224205
2.

Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat.

Olesen R, Vigano S, Rasmussen T, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.

J Virol. 2015 Jul 29. pii: JVI.01484-15. [Epub ahead of print]

PMID:
26223643
3.

Persisting high prevalence of pneumococcal carriage among HIV-infected adults receiving antiretroviral therapy in Malawi: a cohort study.

Heinsbroek E, Tafatatha T, Phiri A, Ngwira B, Crampin AC, Read JM, French N.

AIDS. 2015 Jul 24. [Epub ahead of print]

PMID:
26218599
4.

Reduced SIV replication in macrophages of sooty mangabeys is associated with increased expression of host restriction factors.

Mir KD, Mavigner M, Wang C, Paiardini M, Sodora DL, Chahroudi AM, Bosinger SM, Silvestri G.

J Virol. 2015 Jul 22. pii: JVI.00710-15. [Epub ahead of print]

PMID:
26202248
5.

What Will It Take to Cure HIV?

Ananworanich J.

Top Antivir Med. 2015 May-Jun;23(2):80-4.

6.

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.

Mesplède T, Wainberg MA.

Viruses. 2015 Jul 7;7(7):3703-18. doi: 10.3390/v7072790. Review.

7.

Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy.

Wong VC, Fong LE, Adams NM, Xue Q, Dey SS, Miller-Jensen K.

Cell Mol Bioeng. 2014 Sep 1;7(3):320-333.

PMID:
26191086
8.

Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells.

Iordanskiy S, Van Duyne R, Sampey GC, Woodson CM, Fry K, Saifuddin M, Guo J, Wu Y, Romerio F, Kashanchi F.

Virology. 2015 Jul 14;485:1-15. doi: 10.1016/j.virol.2015.06.021. [Epub ahead of print]

PMID:
26184775
9.

Expansion of SIV-specific CD8 T cell lines from SIV-naïve Mauritian cynomolgus macaques for adoptive transfer.

Mohns MS, Greene JM, Cain BT, Pham NH, Gostick E, Price DA, O'Connor DH.

J Virol. 2015 Jul 15. pii: JVI.00993-15. [Epub ahead of print]

PMID:
26178985
10.

Is HEV an emerging problem in industrialized countries?

Sayed IM, Vercouter AS, Abdelwahab SF, Vercauteren K, Meuleman P.

Hepatology. 2015 Jul 14. doi: 10.1002/hep.27990. [Epub ahead of print]

PMID:
26175182
11.

Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients.

Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V.

Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01077-15. [Epub ahead of print]

PMID:
26169416
12.

Rapid development of gp120-focused, neutralizing B cell responses during acute simian immunodeficiency virus infection of African green monkeys.

Amos JD, Himes JE, Armand L, Gurley TC, Martinez DR, Colvin L, Beck K, Overman RG, Liao HX, Moody MA, Permar SR.

J Virol. 2015 Jul 8. pii: JVI.01564-15. [Epub ahead of print]

PMID:
26157116
13.
14.

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST.

MBio. 2015 Jul 7;6(4). pii: e00465-15. doi: 10.1128/mBio.00465-15.

15.

A passive-flow microfluidic device for imaging latent HIV activation dynamics in single T cells.

Ramji R, Wong VC, Chavali AK, Gearhart LM, Miller-Jensen K.

Integr Biol (Camb). 2015 Jul 3. [Epub ahead of print]

PMID:
26138068
16.

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP.

PLoS Pathog. 2015 Jul 2;11(7):e1005000. doi: 10.1371/journal.ppat.1005000. eCollection 2015 Jul.

17.

CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.

Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP.

J Int AIDS Soc. 2015 Jun 29;18:20052. doi: 10.7448/IAS.18.1.20052. eCollection 2015.

18.

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell-Vaccine Induced T-Cell Responses.

Andrés C, Plana M, Guardo AC, Alvarez-Fernández C, Climent N, Gallart T, León A, Clotet B, Autran B, Chomont N, Gatell JM, Sánchez-Palomino S, García F; for DCV2/MANON07-ORVACS study group.

J Virol. 2015 Jun 24. pii: JVI.01062-15. [Epub ahead of print]

PMID:
26109727
19.

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.

Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B.

Expert Opin Biol Ther. 2015 Jul;15 Suppl 1:13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22.

PMID:
26096836
20.

CD4+CD25+CD127 regulatory cells play multiple roles in maintaining HIV-1 p24 production in patients on long-term treatment: HIV-1 p24-producing cells and suppression of anti-HIV immunity.

Jiao YM, Liu CE, Luo LJ, Zhu WJ, Zhang T, Zhang LG, Su LS, Li HJ, Wu H.

Int J Infect Dis. 2015 Jun 19;37:42-49. doi: 10.1016/j.ijid.2015.06.008. [Epub ahead of print]

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk